Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AstraZeneca ( (GB:AZN) ) has shared an announcement.
AstraZeneca reported positive Phase III EMERALD-3 data showing that a regimen combining its immunotherapies Imfinzi and Imjudo with lenvatinib and transarterial chemoembolisation significantly improved progression-free survival versus embolisation alone in patients with unresectable, embolisation-eligible hepatocellular carcinoma. Early overall-survival data show a favourable trend, with additional trial arms also indicating potential benefit, reinforcing the STRIDE dual-immunotherapy backbone in earlier-stage liver cancer and supporting ongoing regulatory discussions that could further strengthen AstraZeneca’s competitive position in liver oncology if confirmed by final outcomes and safety data.
The EMERALD-3 results build on prior HIMALAYA data in more advanced disease, suggesting that moving STRIDE earlier in the treatment pathway may help delay progression and recurrence in a large patient group that currently lacks effective systemic options alongside embolisation. With safety findings consistent with known profiles and plans to present the data at an upcoming medical meeting, the company is poised to leverage these results to expand Imfinzi and Imjudo’s use in hepatocellular carcinoma, a major global cause of cancer death where more than 200,000 patients annually could be eligible for this combined approach.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines, particularly in oncology, cardiovascular, renal and metabolic diseases, and respiratory and immunology. Its oncology franchise includes the immunotherapies Imfinzi and Imjudo, which are already approved across multiple lung, liver, biliary tract and bladder cancer indications worldwide.
See more insights into AZN stock on TipRanks’ Stock Analysis page.